Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Boston Scientific Launches Neuroform EZâ„¢ Stent System in U.S. and Europe

July 26, 2010 4:34 am | by Boston Scientific | News | Comments

Company expands market-leading family of neurovascular stents

TOPICS:

Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study

July 26, 2010 3:36 am | by Bio-Medicine.Org | News | Comments

EMERYVILLE, Calif. , July 26 /- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma....

TOPICS:

Delcath Systems Announces Second Quarter Progress Report Conference Call

July 26, 2010 3:36 am | by Bio-Medicine.Org | News | Comments

NEW YORK , July 26 /- Delcath Systems, Inc. (Nasdaq: DCTH ) announced today that it will host a conference call to discuss its second quarter results and recent corporate developments on Thursday, July 29, 2010 at 4:30pm, ET . Eamonn Hobbs , President and Chief Executive Officer, and...

TOPICS:
Advertisement

Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity

July 26, 2010 3:36 am | by Bio-Medicine.Org | News | Comments

TEMPE, Ariz. , July 26 /- Harco Metal Products (Harco), an industry leader in tube fabrication, systems integration, and seamless, cost effective manufacturing, announced today the contract to manufacture MediGLIDERâ„¢ products for ConMediSys. ConMediSys, the developer of safety...

TOPICS:

Gamma-Tocotrienol Kills Prostate Cancer Stem Cells

July 26, 2010 12:33 am | by Bio-Medicine.Org | News | Comments

SINGAPORE , July 25 /PRNewswire-Asia/ -- Scientists from Singapore , Australia and Hong Kong have found that gamma-tocotrienol is potent in killing prostate cancer stem cells. This small group of cells is responsible for the initiation of prostate cancer and is resistant to conventional...

TOPICS:

2008 U.S. Diabetes Drug Delivery - Patient Perspective

July 26, 2010 12:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK , July 26 /- Reportlinker.com announces that a new market research report is available in its catalogue: 2008 U.S. Diabetes Drug Delivery - Patient Perspective http://www.reportlinker.com/p0236248/2008-US-Diabetes-Drug-Delivery---Patient-Perspective.html This...

TOPICS:

San Diego Businesses Receive Health Care Reform Notices From IRS

July 26, 2010 12:32 am | by San Diego Business Journal | News | Comments

One of the first provisions of the Healthcare Reform Act to go into effect may provide relief for many San Diego employers in the form of a small business tax credit designed to assist with the cost of providing health insurance to employees, according to Notice 2010-44 issued by the...

TOPICS:

The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen

July 26, 2010 12:32 am | by EurekAlert | News | Comments

(The Translational Genomics Research Institute) The Marilyn B. Gula Mountains of Hope Foundation continues its fight against advanced breast cancer with a $50,000 donation to the Phoenix-based Translational Genomics Research Institute (TGen), for a total contribution over two years of $300,000.

TOPICS:
Advertisement

Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children

July 25, 2010 9:33 pm | by EurekAlert | News | Comments

(Children's Hospital of Philadelphia) School-aged children who undergo cardiopulmonary bypass during surgery for less complicated congenital heart defects do not appear to suffer any impairments in neurocognitive abilities, such as intelligence, memory, motor skills and behavior....

TOPICS:

Diagnostic 'guidelines' a barrier to prompt relief for some back pain

July 24, 2010 4:34 pm | by EurekAlert | News | Comments

(Johns Hopkins Medical Institutions) Slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as $10,000 per patient, new Johns Hopkins-led research suggests.

TOPICS:

Intuitive Surgical expands repurchase(3)

July 23, 2010 4:45 pm | by The Associated Press | News | Comments

Intuitive Surgical Inc. said Friday that its board authorized the repurchase of an additional $150 million of its stock.The authorization brings the company's amount of stock available for repurchase to $300 million.Shares of the surgical robot maker rose $17.39, or 5.5 percent, to close at...

Education Tactics for Thought Leaders, Physicians, Patients and Payers to Support Successful Oncology Product Launches

July 23, 2010 4:37 pm | by Bio-Medicine.Org | News | Comments

CHAPEL HILL, N.C. , July 23 /- The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that...

TOPICS:

BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial

July 23, 2010 4:36 pm | by Bio-Medicine.Org | News | Comments

HERNDON, Va. , July 23 /PRNewswire-USNewswire/ -- BHR Pharma, LLC (BHR) announced today that the first patient has been enrolled in its SyNAPSe study ( www.synapse-trial.com ), a global, Phase 3, pivotal trial to evaluate the safety and effectiveness of its intravenous progesterone...

TOPICS:

Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer

July 23, 2010 4:36 pm | by Bio-Medicine.Org | News | Comments

GREAT NECK, N.Y. , July 23 /PRNewswire-USNewswire/ -- The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with cancer of the oropharynx (back of the mouth) to participate in a Phase I clinical trial. Subjects must be newly diagnosed...

TOPICS:

Vermillion Announces Relocation of Corporate Offices to Austin, Texas

July 23, 2010 4:35 pm | by Bio-Medicine.Org | News | Comments

FREMONT, Calif. , July 23 /- Vermillion, Inc. (Nasdaq: VRML ), a molecular diagnostics company, today announced that it is relocating its corporate headquarters from Fremont, California to Austin, Texas .  Vermillion has executed a two-year lease for a new principal place of business...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading